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SCIENTIFIC OPINION 
Scientific Opinion on bovine lactoferrin
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to carry out the additional assessment for „lactoferrin‟ as a food ingredient in the 
context of Regulation (EC) No 258/97 taking into account the comments and objections of a scientific nature 
raised by Member States. Bovine lactoferrin (bLF) is a protein that occurs naturally in cow‟s milk. The applicant 
intends to market bLF that is isolated from cheese whey and skimmed milk, and purified. The applicant intends 
to add bLF to foods for particular nutritional uses, i.e. infant and follow-on formulae, dietary food for special 
medical purposes, dairy products, yoghurts and yoghurt drinks, and chewing gums. According to the applicant, 
the high intake estimate for infants would be 1.1 g bLF per day. For adults, the applicant‟s calculation estimates 
a mean and 97.5
th
 percentile intake of 0.6 and 2.1 mg/kg bodyweight per day, respectively, and a mean and 97.5
th
 
percentile daily intake of about 45 mg and 150 mg, respectively. The Panel notes that the safety of bLF as a 
novel food ingredient has already been assessed with a favourable outcome. That evaluation was to a significant 
extent based on safety data on bLF produced by Morinaga. The Panel also notes that the applicant intends 
maximum use levels of bLF in foods which are equivalent or lower than those intended by the applicant of the 
previous Opinion, and that the range of foods to which it is intended to add bLF is smaller. Consequently, the 
estimated intake levels described for the present application are comparable for infants and lower for all other 
population groups. The Panel concludes that the novel food ingredient, bLF, is safe under the proposed uses and 
use levels. 
© European Food Safety Authority, 2012. 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to carry out the additional assessment for „lactoferrin‟ as a food 
ingredient in the context of Regulation (EC) No 258/97 taking into account the comments and 
objections of a scientific nature raised by Member States.  
Bovine lactoferrin (bLF) is a protein that occurs naturally in cow‟s milk. The applicant intends to 
market bLF in isolated and purified form. Batch testing confirmed that the product complies with the 
given specifications. Bovine lactoferrin from whey cheese or skimmed milk is concentrated via ion 
exchange and is subsequently subjected to filtration steps. Ultimately the bLF is dried by means of 
freeze-drying, milled, or sieved. The applicant provided sufficient information regarding the 
specification, manufacture, composition and stability of bLF. 
The applicant intends to add bLF to foods for particular nutritional uses, i.e.  infant and follow-on 
formulae, dietary food for special medical purposes, and foods such as fermented milks (e.g. 
buttermilk and fermented milk drinks) and non fermented milk drinks, ice cream, yoghurts and 
yoghurt drinks, and chewing gums. The intended maximum levels are 1,000 mg/L for infant 
formulae, 3000 mg/100 g for chewing gums and 133 mg/100g for dairy products.  
According to the applicant, the high intake estimate for infants would be 1.1 g bLF per day. For 
infants of 6 to 12 months consuming follow-on formula, the applicant anticipated that the intakes on 
an absolute and body weight basis would be less than those for infants consuming solely formula 
milk, since the consumption of infant formulae per kg bodyweight decreases with the age of the 
infants. For male adults, the applicant‟s calculation estimates a mean and 97.5th percentile intake of 
0.6 and 2.1 mg/kg bodyweight per day, respectively, and a mean and 97.5
th
 percentile daily intake of 
about 45 mg and 150 mg, respectively.  
The toxicological studies conducted were an Ames test study, a single dose oral toxicity study in rats 
and a four-week and a thirteen-week repeated dose oral toxicity study in rats. The Panel considers 
that the evidence provided does not raise safety concerns. 
The Panel notes that the safety of bLF as a novel food ingredient has already been assessed with a 
favourable outcome (EFSA, 2012). That evaluation was to a significant extent based on safety data 
on bLF produced by Morinaga. The Panel also notes that the applicant intends maximum use levels of 
bLF in foods which are equivalent (infant formula) or lower than those intended by the applicant of 
the previous Opinion, and that the range of foods to which it is intended to add bLF is smaller. 
Consequently, the estimated intake levels described for the present application are comparable for 
infants and lower for all other population groups.  
The Panel concludes that the novel food ingredient, bLF, is safe under the proposed uses and use 
levels. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 2 March 2011, the company Morinaga Milk Industry Co., Ltd. submitted a request under Article 4 
of Novel Food Regulation (EC) N° 258/97 to place on the market „lactoferrin‟ as a novel food 
ingredient. 
 
On 22 June 2011, the competent authorities of Ireland forwarded to the Commission their initial 
assessment report, which came to the conclusion that for „lactoferrin‟ an additional assessment was 
required in order to consider this application in conjunction with an earlier application concerning 
„lactoferrin‟. 
In consequence, a Community Decision is now required under Article 7, paragraph 1 of Regulation 
(EC) No 258/97.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety 
Authority is asked to carry out the additional assessment for „lactoferrin‟ as a food ingredient in the 
context of Regulation (EC) N° 258/97. 
EFSA is asked to carry out the additional assessment.  
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ASSESSMENT 
In accordance with Commission Recommendation 97/618/EC, „bovine lactoferrin (bLF)‟ is allocated 
to Class 2.1 as „a complex (non-GM derived) novel food ingredient, the source of the novel food 
having a history of food use in the community‟. The assessment of the safety of this novel food 
ingredient is based on data supplied in the original application and the initial assessment by the 
competent authority of Ireland. The data are required to comply with the information required for 
novel foods of Class 2.1 i.e. structured schemes I, II, III, IX, X, XI, XII and XIII as indicated by 
Regulation (EC) No 258/97. It is noted that the novel food ingredient (NFI) is intended by the 
applicant to be added to foods for particular nutritional uses (PARNUTS), i.e. infant and follow-on 
formulae, dietary food for special medical purposes, and foods such as fermented milks (e.g. 
buttermilk and fermented milk drinks) and non fermented milk drinks, ice cream, yoghurts and 
yoghurt drinks, and chewing gums, to improve immune health. This assessment concerns only risk 
that might be associated with consumption and is not an assessment of the efficacy of bLF with regard 
to any claimed benefit. 
The Panel notes that the safety of bLF as a novel food ingredient has already been assessed with a 
favourable outcome (EFSA, 2012). That evaluation was to a significant extent based on safety data on 
bLF produced by Morinaga. Where applicable the present opinion makes reference to that assessment.   
1. SPECIFICATION OF THE NOVEL FOOD (NF) 
Bovine lactoferrin is a protein that occurs naturally in cow‟s milk. The applicant intends to market 
bLF in isolated and purified form. It is an iron-binding glycoprotein of approximately 77 kDa and 
consists of a single polypeptide chain of 689 amino acids; the sequence homology with human 
lactoferrin is 69 % (Pierce et al., 1991). 
 
The protein does not contain free sulphydryl groups but it has intramolecular disulphide bonds. It is 
glycosylated at two different sites by N-linked glycans of the N-acetyllactosamine type. These glycans 
are characterized by α-1,3-linked galactose residues at the terminal non-reducing position. Unlike 
human lactoferrin, bLF also contains glycans of the oligomannosidic type.  
The tertiary structure of this glycoprotein has two iron-binding sites, giving it the capability to bind 
two Fe
3+
 ions per molecule of protein. 
The applicant specifies the novel food ingredient as follows, and the contents are expressed as 
percentage by weight. The pink, odourless powder contains at least 94.5 % protein, at least 96 % of 
which is bFL (Table 1). 
Table 1:  Specification for the novel food ingredient  
Parameter Units Specification Method of Analysis 
Appearance Visual Pink and odourless 
powder 
Visual Inspection 
Total Protein  % (dry weight basis, N 
x 6.38) 
Min. 94.5 Kjeldahl method (N x 6.38) 
Purity (lactoferrin) % w/w of total protein Min. 96.0 HPLC (per protein) 
Total lactoferrin % w/w Min. 90.7 Calculation
 
Ash % (dry weight basis) Max. 1.3 Heat to >550°C 
Loss on Drying % w/w Max. 4.2 Heat to 150°C 
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pH (2% solution w/w) pH units 5.2 to 7.2 pH meter 
Iron Content mg/ 100 g Max. 35 ICP 
Arsenic mg/kg Max. 2 ICP-MS 
Heavy metals as Lead mg/kg Max. 20* ICP-MS 
Total bacteria cfu/g Less than 1,000 Standard agar 
Coliform bacteria per 0.1 g Negative Desoxicholate agar 
Coagulase positive 
staphylococci 
per 0.01 g Negative Mannitol salt agar with egg 
yolk 
Yeast cfu/g Less than 30 Potato dextrose agar 
Moulds cfu/g Less than 30 Potato dextrose agar 
* Maximum limit in accordance with Regulation (EC) No 1881/2006 
 
The information on the physical and chemical properties of the ingredient are given below in Table 2 
and were adopted by the applicant from Naidu (2000).   
Table 2:  Physical-chemical properties of bLF  
Property bLF Reference 
Molecular mass (kDa)   
     Sedimentation co-efficient 72,200 ± 1,300 Castellino et al., 1970 
     SDS-Page 76,000 ± 2,400 Querinjean et al., 1971 
     Iron titration 78,500 Aisen et Leibman, 1972 
Isoelectric point   
     Chromato focusing 8.2 – 8.9 Shimazaki et al., 1993 
     Isoelectric focusing 9.5 – 10.0 Yoshida et Xiuyun, 1991  
Absorption spectra  Aisen et Leibman, 1972 
     Apo-form at 280 nm 12.7  
     Holo-form at 470 nm 0.400  
Protease sensitivity Relatively low* Brines et Brock, 1983 
Iron-binding  Aisen et Leibman, 1972 
     Equilibrium dialysis (K1 x 10
-4
) 3.73  
Thermal denaturation  Paulsson et al., 1993 
    Apo-LF denaturation (Tmax: °C) 71 ± 0.3 and 90 ± 0.3  
    Apo-LF enthalpy (∆Hcal: J/g) 12 ± 0.4 and  2 ± 0.5  
    Holo-LF denaturation (Tmax: °C) 65 ± 0.3 and 93 ± 0.3  
    Holo-LF enthalpy (∆Hcal: J/g)    2 ± 1 and 37 ± 1  
*The original table by Naidu (2000) indicated a “high” protease sensitivity, but the original reference (Brines and Brock, 
1983) points to a low protease sensitivity of bLF towards intestinal proteases. The applicant suggested amending the 
table accordingly. 
 
Chemical properties vary with the amount of bound iron. The analytical data from three production 
lots produced in November 2005 and in January and July 2008 (Table 3) show that the protein content 
varied from 98.3 to 99.6 %. 
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Table 3:  Analytical data from the testing of three batches each from cheese whey and skimmed 
milk. 
Parameter Units 
Analytical Results 
Methods of Analysis 
bLF from Cheese Whey bLF from Skimmed Milk 
Batch 1 Batch 2 Batch 3 Batch 1 Batch 2 Batch 3  
Protein % w/w 99.4 98.3 99.0 98.7 99.5 99.6 Kjeldahl method (N x 
6.38) 
Lactoferrin 
(purity) 
% w/w of total 
protein 
97.1 97.1 96.3 97.5 97.6 97.2 HPLC 
Total 
lactoferrin 
% w/w 96.5 95.4 95.3 96.2 97.1 96.8 Calculation
1 
Fat  % w/w <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 Rose Gottlieb method 
Ash  % w/w (dry 
weight) 
0.26 0.26 0.23 0.80 0.33 0.45 Heat to >550°C 
Loss on 
drying 
% w/w 0.44 0.58 0.14 1.85 0.85 0.46 Heat to 150°C 
Iron  mg/100 g 23.3 23.4 20.5 10.9 11.1 10.6 ICP 
pH pH units 5.58 5.86 5.80 6.92 5.82 6.10 pH meter 
Inorganics and Minerals 
Sodium  mg/100 g 55.5 28.9 46.7 178 71.5 118 ICP 
Potassium  mg/100 g 18.20 2.13 3.60 11.5 2.53 4.95 ICP 
Magnesium mg/100 g 1.14 0.63 1.47 7.08 1.65 2.04 ICP 
Phosphate  mg/100 g 4.5 3.13 6.97 3.35 11.5 6.21 ICP 
Calcium  mg/100 g 15.5 7.66 18.6 75.6 18.1 23.0 ICP 
Chloride  mg/100 g 813 805 779 914 799 845 Potentiometric 
titration method 
Copper  mg/100 g 0.09 0.12 0.91 nd 
(<0.05) 
nd 
(<0.05) 
nd 
(<0.05) 
ICP 
Zinc   mg/100 g 0.17 0.12 0.94 0.28 0.22 0.22 ICP 
Manganese mg/100 g 0.008 nd 
(<0.003) 
nd 
(<0.003) 
0.013 0.006 0.007 ICP 
HPLC = High Performance Liquid Chromatography; ICP = inductively coupled plasma; nd = not detected 
1 Total lactoferrin content = lactoferrin (purity of total protein content, %) x protein content (%). 
 
 
Minor compounds [lactogenin-like protein, angiogenin, insulin-like growth factor-binding protein 
(IGFbp)] of the residual protein fraction were detected with gel electrophoresis tests. 
According to the dossier, the iron saturation is less than 25 % and the iron content varied from 10.6 to 
23.4 mg/100 g. 
The applicant provided satisfactory analytical data on levels of contaminants. The analyses included 
heavy metals, mycotoxins, dioxins and dioxin-like PCBs, pesticides and chlorinated hydrocarbons. 
All foods, and hence also novel foods, have to comply with the existing legislation.  
The Panel considers that the information provided on the composition, specification and data from 
batch testing do not raise concerns.  
2. EFFECT OF THE PRODUCTION PROCESS APPLIED TO THE NF  
The applicant provided information on the production process of bLF derived from cheese whey or 
skimmed milk. After the selective isolation of lactoferrin from these sources, the subsequent 
purification processes are identical. 
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Initially, skimmed milk is cooled before undergoing filtration. Lactoferrin is isolated by ion exchange 
chromatography from cheesed (sweet) whey or skimmed milk, respectively, before undergoing a 
series of demineralisation stages and pasteurisation to yield the novel ingredient.  After selective 
isolation of lactoferrin from either cheese whey or skimmed milk, the subsequent purification process 
are identical.  All processes employed are physical separation and pasteurisation techniques common 
to the dairy industry.  In particular, the isolation process is analogous to that employed in whey 
protein concentrate production, except that the conditions are optimised for selective purification of 
lactoferrin.   
According to the applicant, the production of bLF is conducted consistent with current good 
manufacturing practices (GMP) and the principles of Hazard Analysis Critical Control Point 
(HACCP), and all practices employed are in compliance with the relevant hygiene legislation. 
Stability 
The applicant provided analytical data (using an ELISA) on three batches of lactoferrin isolated from 
cheese whey and one batch from skimmed milk when stored in aluminium bags at room temperature 
for at least 36 months. In addition, data were provided on the stability of three batches of lactoferrin 
added to yoghurt and stored for 16 days under refrigerated conditions, of one batch added to dried 
skimmed milk stored for 46 months, and of three batches added to a commercial infant formula and 
stored for 24 or 36 months. Most of the results showed a recovery rate of close to 100 % (90 to 
103 %).  
The Panel concludes that the production process is sufficiently described by the applicant and does 
not raise safety concerns. 
3. HISTORY OF THE ORGANISM USED AS A SOURCE  
The source of the novel food is milk from cows. The applicant indicates that the milk meets all the 
relevant applicable criteria of European legislation. 
4. ANTICIPATED INTAKE/EXTENT OF THE USE OF THE NF 
The applicant intends to add bLF to foods for particular nutritional uses (PARNUTS), i.e.  infant and 
follow-on formulae, dietary food for special medical purposes, and foods such as fermented milks 
(e.g. buttermilk and fermented milk drinks) and non fermented milk drinks, ice cream, yoghurts and 
yoghurt drinks, and chewing gums. 
Table 4 shows a list of the proposed product groups with the maximum levels of bLF, expressed in 
mg per 100 g end product.  
Table 4:  Intended use categories of the NFI in foods and beverages and the maximum intended 
 usage levels per category 
Food Category Proposed Food 
Use 
Maximum Use-
Level (mg/serving) 
Serving Size
1
 (g) Maximum Use-
Level mg/100 g 
Milk and milk 
products 
Fermented milks
2 
100 200 50 
Ice-cream 100 75 133 
Milk beverages
3 
100 200 50 
Milk powders and 
milk-based 
60
4 
200 (RTD) 30 (RTD) 
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powdered drink 
mixes 
 20 (Powder) 
 
300 (Powder) 
Yoghurts 100 125 80 
Yoghurt drinks 100 200 50 
Sugar confectionery Chewing gums 60 2 3,000 
Foods for Particular 
Nutritional Uses 
(PARNUTS) 
Foods for special 
medical purposes 
(FSMP) 
Depending on the nutritional needs of the individual up to a 
maximum level of 3 g/day 
Infant formulae and 
follow-on formulae 
Formulae (powder):               30 -  770 mg/100 g 
Prepared (liquid) formulae:    40 - 1,000 mg/L 
RTD = Ready to drink;  
1 Serving sizes are based on food portion sizes established by the Food Standards Agency (FSA, 2002), unless otherwise 
specified; 
2 The NDNS databases (Office for National Statistics, 2005; UKDA, 1995, 2001); do not include food codes under the group 
“fermented milks” specifically, and food codes for “buttermilk” and “yakult” were used as surrogates to represent these 
types of products on the UK market;  
3 The applicant indicated that the target products are “fortified-type milk beverages” either provided as one or multiple 
servings, and food code selection was therefore limited to specific milk drink products or fortified milks as surrogates 
for the intended use, and did not include plain milks; 
4 Use-levels based on reconstituted dried milk beverages (i.e. providing 60 mg lactoferrin per 200 g serving). 
 
The applicant provided an assessment of the consumption of bLF measured as the total intake of the 
ingredient maximally dosed in products, which was conducted based on the proposed food uses and 
use-levels summarised in Table 4.  
Calculations for the mean and high-level (97.5
th
 percentile) all-person and all-user intakes, and 
percent consuming were performed for each of the individual proposed food-uses for bLF and for all 
food-uses combined.  The estimated per person and per kilogram body weight intakes were calculated 
for various population groups based on consumption data from the United Kingdom [(NDNS 2000-
2001, Office for National Statistics, 2005); (NDNS 1992-1993, UKDA, 1995); (NDNS 1997, UKDA, 
2001)]. 
The use in foods for special medical purposes (FSMPs) was excluded from the intake assessment on 
the basis that these products would be consumed as partial or complete replacements for conventional 
foods, rather than in combination with them, and because the dietary needs of the individual would be 
different to those of the general population.  For the exposure assessment of bLF from chewing gums, 
the applicant conservatively assumed that the ingredient maximally dosed is consumed either by 
leaching during the chewing process or by swallowing the gums. 
The applicant provided high-intake data for infant formulae of 1,060 mL (Kersting et al., 1998) and 
1,200 g per day (IOM, 1991)   Based on these two references, EFSA has estimated a mean intake for 
infant formula of 800 g per day and a rounded high value of 1100 g per day (EFSA, 2010). 
Considering the proposed maximum concentration of 1000 mg/L, the resulting high intake estimate 
for infants would be 1.1 g bLF per day. For infants of 6 to 12 months consuming follow-on formula, 
the applicant anticipated that the intakes on an absolute and body weight basis would be less than 
those for infants consuming solely formula milk, since the consumption of infant formulae per kg 
bodyweight decreases with the age of the infants.  
Table 5 summarises the estimated total intake of bLF (g/person/day) from all proposed food-uses.  
Table 5 presents this data on a per kilogram body weight basis (mg/kg body weight/day).  Consistent 
with bLF being intended for use as a food ingredient in only a limited range of foods for the general 
population (i.e. dairy products only, with the exception of chewing gums), the percentage of users was 
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moderate among all the population groups evaluated in the current assessment.  According to the 
application, each population group had 45.5 % or more identified users of food products in which bLF 
is proposed for use; Children of 4-10 years were identified as the population group containing the 
greatest percentage of users at 74.6 %, followed by female teenagers at 63.2 % and male teenagers at 
60.3 %.  Moderate user percentages within a population group typically lead to dissimilar results for 
the all-person and all-user consumption estimates, and therefore it is the all-user estimates that are 
more applicable to the assessment of safety as they are more likely to represent exposure in the target 
populations. 
Of the individual population groups, male adults were determined to have the greatest mean and 97.5
th
 
percentile all-user intakes of 47 and 150 mg/person/day (0.6 and 2 mg/kg body weight/day), 
respectively.  Female teenagers had the lowest mean and 97.5
th
 percentile all-user intakes of 30 and 
112 mg/person/day (0.6 and 2.4 mg/kg body weight/day), respectively (Tables 5 and 6). 
Table 5:  Estimated daily intake of bLF (mg) in UK population groups from food products 
 intended to be fortified, as provided by the applicant based on NDNS consumption data 
 (1992-1993, 1997, 2000-2001). 
Population 
Group 
Age 
Group 
(Years) 
% 
User 
Actual 
# of 
Total 
Users 
All-Person Consumption All-Users Consumption 
Mean 
(mg) 
Percentile (mg) Mean 
(mg) 
Percentile (mg) 
90th 95th 97.5th  90th 95th  97.5th  
Children 1½ - 4½ 57.9 955 23 68 88 110 40 85 103 124 
Young People 4-10 74.6 624 28 72 93 111 37 81 100 118 
Female 
Teenagers 
11-18 63.2 282 19 57 74 97 30 68 83 112 
Male 
Teenagers 
11-18 60.3 251 24 73 107 125 39 95 123 136 
Female Adults 16-64 51.6 494 24 72 100 124 44 97 120 143 
Male Adults 16-64 45.6 349 23 69 92 114 47 98 120 150 
 
Table 6:  Estimated daily intake of bLF (mg/kg bw per day) in UK population groups from food 
 products intended to be fortified, as provided by the applicant based on NDNS 
 consumption data (1992-1993, 1997, 2000-2001). 
Population 
Group 
Age 
Group 
(Years) 
% 
User 
Actual 
# of 
Total 
Users 
All-Person Consumption All-Users Consumption 
Mean 
(mg/kg) 
Percentile (mg/kg bw) Mean 
(mg/kg) 
Percentile (mg/kg bw) 
90th 95th 97.5th  90th 95th  97.5th  
Children 1½ - 4½ 57.9 955 1.6 4.8 6.6 7.7 2.8 6.2 7.4 8.6 
Young People 4-10 74.6 624 1.1 2.7 3.6 4.5 1.5 3.1 4.4 5.1 
Female 
Teenagers 
11-18 
63.2 282 
0.4 1.1 1.4 2.0 0.6 1.3 1.7 2.4 
Male 
Teenagers 
11-18 
60.3 251 
0.5 1.5 1.9 2.5 0.8 1.8 2.3 2.7 
Female Adults 16-64 51.6 494 0.3 1.1 1.4 1.9 0.6 1.4 1.9 2.1 
Male Adults 16-64 45.6 349 0.3 0.8 1.1 1.5 0.6 1.2 1.5 2.0 
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The Panel notes that this type of intake methodology for fortified foods is generally considered to be 
“high intake”, as a result of several conservative assumptions made in the consumption estimates 
where it is assumed that all food products within a food category contain the ingredient at the 
maximum specified level of use. However, with regard to infants, the intake estimate is considered to 
be realistic also in real life.   
The Panel notes that the intake estimates are, with the exception of the intake estimates for infants, 
lower than those of a previous application for bLF (EFSA 2012). The difference can be explained by 
lower levels of intended maximum concentrations, less food categories to which it is intended to add 
bLF, and different food consumption data used (UK data versus data from the Netherlands used a 
previous application for bLF (EFSA, 2012). 
5. INFORMATION FROM PREVIOUS EXPOSURE TO THE NF OR ITS SOURCE 
The Panel refers to its previous assessment of bLF as a novel food ingredient (EFSA, 2012).  
6. NUTRITIONAL INFORMATION ON THE NF 
The Panel refers to its previous assessment of bLF as a novel food ingredient (EFSA, 2012). Based on 
the information provided on the protein nature and the proposed use levels, the Panel considers that 
the intake of bLF is not nutritionally disadvantageous. 
7. MICROBIOLOGICAL INFORMATION ON THE NF 
The applicant provided information on the microbiological analysis of each of three batches of bLF 
derived from cheese whey and skimmed milk. The Panel has no safety concerns with regard to the 
microbiological specifications of bLF. 
8. TOXICOLOGICAL INFORMATION ON THE NF 
The Panel notes that the toxicological data on bLF produced by Morinaga Milk Industry Co., Ltd. 
have been evaluated in a previous Opinion on the safety of bLF as a novel food ingredient (EFSA, 
2012). The toxicological studies conducted were an Ames test study  (Kawai, 1997; Yamauchi et al., 
2000a), a single dose oral toxicity study in rats (Nishimura, 1991) and a four-week (Nishimura, 1997) 
and a thirteen-week (Nishimura, 1998; Yamauchi et al., 2000b) repeated dose oral toxicity study in 
rats. The Panel considers that the evidence provided does not raise safety concerns. 
8.1. Human studies 
The Panel refers to its previous assessment of bLF as a novel food ingredient (EFSA, 2012). The 
Panel notes that no adverse effects related to bLF have been reported in nineteen studies in adults 
which were not designed to study the safety of bLF. 
8.2. Allergenicity  
The Panel refers to its previous assessment of bLF as a novel food ingredient (EFSA, 2012). The 
Panel considers that the risk of allergic reactions is not dissimilar to other dairy products derived from 
bovine sources. 
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DISCUSSION 
The Panel notes that the safety of bLF as a novel food ingredient has already been assessed with a 
favourable outcome (EFSA, 2012). That evaluation was to a significant extent based on safety data on 
bLF produced by Morinaga. The Panel also notes that the applicant intends maximum use levels of 
bLF in foods which are equivalent (infant formula) or lower than those intended by the applicant of 
the previous Opinion, and that the range of foods to which it is intended to add bLF is smaller. 
Consequently, the estimated intake levels described for the present application are comparable for 
infants and lower for all other population groups. 
CONCLUSIONS 
The Panel concludes that the novel food ingredient, bLF, is safe under the proposed uses and use 
levels. 
DOCUMENTATION PROVIDED TO EFSA 
1. Dossier on „bovine lactoferrin‟ by Morinaga, received on 6 September 2011. Additional 
information was provided on 28 May 2012. 
2. Letter from the European Commission to the European Food Safety Authority with the request 
for an opinion on the safety of the safety of „bovine lactoferrin‟. Ref. Ares (2011)944545 – 
06/09/2011. 
3. Initial assessment report carried out by the competent authority of Ireland which concluded that 
an additional assessment was required (22 June, 2011). 
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GLOSSARY / ABBREVIATIONS 
bw  bodyweight 
bLF  bovine lactoferrin 
NF(I)  novel food (ingredient)  
PARNUTS foods for particular nutritional uses 
FSMP  Foods for special medical purposes 
